- ￥1985
- 熹垣生物
- XY-LC11316
- 2025年07月15日
企业认证
相关产品推荐更多 >
Tenacissoside H
￥100Framycetin (Fradiomycin B)
￥446
1355246-82-0
￥100(1R,3R)-3-[(1Z)-2-Chloro-3,3,3-trifluoro-1-propen-1-yl]-2,2-dimethylcyclopropanecarboxylic Acid (R)-Cyano(3-phenoxyphenyl)methyl Ester-d5 (Cyhalothrin Isomer)
￥100rac-(4R)-4,6-Dihydroxy-2-methyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic Acid-D3 (Impurity)
￥100
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
301648-08-8
- 规格：
1mg
Storage：Store at -20°C
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Isolation of Stem Cells from Human Umbilical Cord Blood
Umbilical cord blood (UCB) is gaining more prominence in recent times as a source of non-embryonic multipotent stem cells. Global annual human birth rate (100 million) presents UCB as the largest non-controversial stem cell source
immature cells that rival the use of bone marrow for reconstitution of blood lineages. Umbilical cord blood (UCB) is emerging as an effective and feasible clinical treatment as its availability increases and benefits are realized. Basic science research
Isolation of Human and Mouse Hematopoietic Stem Cells
. For clinical applications HSC derived from umbilical cord blood (UCB) and G-CSF mobilized peripheral blood (PB) have been demonstrated to have several advantages compared to bone marrow; therefore, they are slowly replacing BM as alternative source of stem
技术资料暂无技术资料 索取技术资料
